



June 8, 2021

Lysonix, Inc.
Ronald Lagerquist
Regulatory Affairs Manager
1170 Mark Ave.
Carpinteria, California 93013

Re: K980771
Trade/Device Name: Lysonix Suction Lipoplasty System
Regulation Number: 21 CFR 878.5040
Regulation Name: Suction lipoplasty system
Regulatory Class: Class II
Product Code: QPB

Dear Ronald Lagerquist:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated July 13, 1998. Specifically, FDA is updating this SE letter because FDA has created a new product code to better categorize your device technology.

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact Cindy Chowdhury, OHT4: Office of Surgical and Infection Control Devices, 240-402-6647, Cindy.Chowdhury@fda.hhs.gov.

Sincerely,

Cindy Chowdhury -S

Cindy Chowdhury, Ph.D., M.B.A.

Assistant Director

DHT4B: Division of Infection Control
and Plastic Surgery Devices

OHT4: Office of Surgical
and Infection Control Devices

Office of Product Evaluation and Quality
Center for Devices and Radiological Health



JUL 13 1998

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Ronald F. Lagerquist
Regulatory Affairs Manager
Lysonix, Inc.
1170 Mark Avenue
Carpinteria, California 93013

Re: K980771
Trade Name: Lysonix Suction Lipoplasty System
Regulatory Class: II
Product Code: MUU
Dated: May 19, 1998
Received: May 22, 1998

Dear Mr. Lagerquist:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Mr. Lagerquist

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read 'C. Witten', with a large, stylized initial 'C' and a horizontal line extending to the right.

Celia M. Witten, Ph.D., M.D.
Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE


Applicant: LySonix, Inc.
510(k) Number: K980771
Device Name: LySonix Suction Lipoplasty System

Indications For Use:

The LySonix Suction Lipoplasty System is intended for use in aesthetic body contouring.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH Office of Device Evaluation (ODE)



(Division Sign-Off)

Division of **General Restorative Devices**

510(k) Number

K980771

Prescription Use
Per 21 CFR 801.109

OR

Over-the-Counter

JUL 13 1998

K980771

510(k) SUMMARY

This 510(k) summary is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR § 807.92

Submitted by: Ronald F. Lagerquist
Regulatory Affairs Manager
LySonix Inc.
1170 Mark Avenue
Carpinteria, CA 93013

Telephone: (805) 684-0409
FAX: (805) 684-0170

Date Prepared: February 25, 1998

Device Name:

Proprietary Name: LySonix Suction Lipoplasty System

Common Name: Suction Lipoplasty System

Indication for Use:

The LySonix Suction Lipoplasty System is intended for use in aesthetic body contouring.

Device Description:

The LySonix Suction Lipoplasty System consists of an Aspiration Pump, Aspiration Cannulas, Sterile Tubing Set, Microbial Filter, Collection Canisters, and Canister Liners.

Substantial Equivalence:

The LySonix Suction Lipoplasty System is substantially equivalent to suction lipoplasty systems described in 21 CFR § 878.5040. The components of the LySonix Suction Lipoplasty System have been found to be substantially equivalent in previously submitted LySonix Inc. 510(k) notifications.